C-Rad ABLTS:0R44 82 ROA % is 8.95% as of Mar. 2026, which is 98% above its 10-year median of 4.52. GuruFocus rates LTS:0R44 with a GF Score™ of 82/100 and a GF Value™ of kr31.78 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 858 Medical Devices & Instruments companies, C-Rad AB ranks better than 74.59% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. C-Rad AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr44.8 Mil.
C-Rad AB's average Total Assets over the quarter that ended in Mar. 2026 was kr500.5 Mil. Therefore, C-Rad AB's annualized ROA % for the quarter that ended in Mar. 2026 was 8.95%.
The historical rank and industry rank for C-Rad AB's ROA % or its related term are showing as below:
LTS:0R44'
s ROA % Range Over the Past 10 Years
Min: -35.52 Med: 4.52 Max: 16.01
Current: 6.08
During the past 13 years, C-Rad AB's highest ROA % was 16.01%. The lowest was -35.52%. And the median was 4.52%.
LTS:0R44's ROA % is ranked better than 74.59% of 858
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs LTS:0R44: 6.08
C-Rad AB (LTS:0R44) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
C-Rad AB ROA % Related Terms
C-Rad AB ROA % Historical Data
* Premium members only.
The historical data trend for C-Rad AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, C-Rad AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's ROA % distribution charts can be found below:
* The bar in red indicates where C-Rad AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
C-Rad AB (LTS:0R44) has a ROA % of 8.95% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on C-Rad AB and its competitors. This is 98% above median its historical median of 4.52. According to the industry distribution chart, C-Rad AB ranks #218 out of 858 companies in the Medical Devices & Instruments industry, placing it in the top 25.4%.
Is C-Rad AB's ROA % too high?
C-Rad AB's current ROA % of 8.95% is 98% above median its 10-year median of 4.52. The Medical Devices & Instruments industry median ROA % is 0.55. C-Rad AB's value of 8.95% is 1542.2% above this industry median. Based on the distribution chart, C-Rad AB ranks #218 out of 858 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #218 out of 858 companies for ROA %. This puts C-Rad AB in the upper half of its industry. The industry median ROA % is 0.55. C-Rad AB's value of 8.95% is 1542.2% above this benchmark. While the company's 10-year median is 4.52 vs. the industry median of 0.55, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current ROA % of 8.95% is 1542.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current ROA % is 8.95%, which is 98% above median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Modestly Overvalued. The stock's GF Value™ is kr31.78, compared to a current price of kr35.90 — trading 13% above its estimated fair value. The current ROA % is 8.95%, which is 98% above median its 10-year median of 4.52 and 1542.2% above the Medical Devices & Instruments industry median of 0.55. C-Rad AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current ROA % is 8.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr35.90 is trading 13% above its estimated GF Value™ of kr31.78.
GuruFocus considers C-Rad AB to be Modestly Overvalued.
Key valuation signals for LTS:0R44:
ROA %: 8.95% (98% above median its 10-year median of 4.52)
GF Value™: kr31.78 vs. price of kr35.90 (13% above fair value)
Industry Position: 1542.2% above the Medical Devices & Instruments median (#218 of 858)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
82GF Score
Get the complete analysis for LTS:0R44
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
